LAV is a biomedical venture capital firm that primarily invests in biopharmaceuticals, human therapeutics, and medical devices, with a core geographic focus on China and increasing investments in the U.S.. Their strategy emphasizes long-term thinking, backing exceptional entrepreneurs, and investing in breakthrough, science-based products, avoiding "quick flip" investments.
50% of their portfolio is in Biotech & Life Sciences. They made 4 investments in the last 12 months. Their most common stage is series-b (75% of deals). Average disclosed round size is $106.0M (across 4 rounds with reported amounts).
Portfolio
4
Fund Size
$2B
Top Stage
Series B
Last 12 Mo
4
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
4 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Syneron Bio | Series B | $150M | Mar 2026 |
 Pinnacle Medicines | Series B | $89M | Mar 2026 |
 QuantX Biosciences, Inc. | Series B | $85M | Feb 2026 |
| OOTR Therapeutics | Series A | $100M | Jun 2025 |
Top Co-Investors
Sanofi Ventures1 shared
Hongshan1 shared
Pfizer Ventures1 shared
Decheng1 shared
Abu Dhabi Investment Authority1 shared
BioTrack Capital1 shared
AstraZeneca1 shared
Sinovation1 shared
5Y Capital1 shared
GL Ventures1 shared
Foresite Capital1 shared
Quan Funds1 shared
HanKang Capital1 shared
RA Capital Management1 shared
Logos Capital1 shared
OrbiMed1 shared
Last updated: 10 April 2026